tenofovir disoproxil and emtricitabine
Sponsors
Gilead Sciences Inc., Merck Sharp & Dohme LLC, Rutgers, The State University of New Jersey, University Hospital, Caen, Africa Health Research Institute
Conditions
Covid19HIV InfectionsHIV-1 InfectionHIV-1 preventionHuman Immunodeficiency Virus (HIV-1) infectionPrEP Adherence Monitoring
Phase 2
Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home
CompletedNCT04685512
Start: 2020-11-18End: 2021-05-01Updated: 2021-07-01
A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Persistence, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for HIV Pre-Exposure Prophylaxis (PrEP) in People Who Would Benefit from PrEP
Active, not recruitingCTIS2023-507891-31-00
Start: 2024-10-11Target: 112Updated: 2025-09-05
Phase 3
Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT
RecruitingNCT06250504
Start: 2024-02-27End: 2026-03-31Target: 2000Updated: 2024-04-17
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
Active, not recruitingCTIS2024-514047-28-00
Start: 2025-01-27Target: 98Updated: 2025-09-12
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
RecruitingCTIS2025-520610-58-00
Start: 2025-11-19Target: 100Updated: 2025-11-12